53,986 Shares in Keros Therapeutics, Inc. $KROS Bought by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 53,986 shares of the company’s stock, valued at approximately $599,000.

A number of other institutional investors have also recently bought and sold shares of KROS. Financial Management Professionals Inc. purchased a new stake in shares of Keros Therapeutics during the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Keros Therapeutics by 264.1% in the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after buying an additional 988 shares during the period. Institutional investors own 71.56% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on KROS. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $20.40.

Insider Activity at Keros Therapeutics

In related news, Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director directly owned 10,958 shares in the company, valued at approximately $117,579.34. The trade was a 19.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at approximately $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,425 shares of company stock worth $89,994. Company insiders own 12.60% of the company’s stock.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $10.22 on Friday. The company has a market capitalization of $202.27 million, a P/E ratio of -3.40 and a beta of 0.97. The business has a fifty day simple moving average of $10.73 and a two-hundred day simple moving average of $12.72. Keros Therapeutics, Inc. has a 1 year low of $9.69 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The firm had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. As a group, analysts anticipate that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.